Supporting a start-up: breakthrough therapy to First-In-Man and beyond

Pulmonary Embolism (PE) affects over 1.2 million people in the US and Europe annually and is a major cause of acute cardiovascular death in the developed world. IVC filters are a commonly used therapy designed to capture clots, preventing them from reaching the lungs and causing PE. The customer has been partnering with the design team at TE since the beginning of their journey as a start-up in 2009. The start-up, developing a unique filter system for the prevention of pulmonary embolism in high risk patients has successfully transitioned through numerous rounds of funding, with the support of TE at each of these phases.

TE's ability to source and manage the supply chain  across its own network of sites for this complex assembly was a critical factor in our selection as the design, development and subsequent manufacture partners for the customer. The design team leverage our vertically integrated supply network to speed up the iterative development process and ensure timely delivery of project milestones. This medtech startup client was subsequently acquired by a global healthcare specialist in an agreement valued up to $150M.